Market

25 % of the world's population suffers from mental illness at some point during their lifetime. Early detection and accurate diagnosis are essential for effective treatment, thus there is a great need for diagnostic decision support in investigations related to schizophrenia and ADHD. Every year, about eight million diagnostic tests related to these conditions are performed, based on incidence and prevalence.

SensoDetect® BERA is currently used in a number of clinics and hospitals in Sweden. SensoDetect's home market is defined as Scandinavia, and will mainly be addressed by SensoDetect’s own sales organization. The intention of the company is to initially expand in Europe. Simultaneously, SensoDetect intends to introduce SensoDetect® BERA to key opinion leaders in America, China and India, to lay the basis for further expansion.

Market: Europe and Scandinavia

In summary, according to the judgement of board of SensoDetect, around 300 000 clinical investigations of psychosis including a question of possible schizophrenia are performed per year in Europe. In addition, over 500 000 neuropsychiatric investigations concerning ADHD are performed. The corresponding estimated numbers for Scandinavia are 12 000 and 21 000, respectively. Consequently, only a minor market share creates significant revenue. Both schizophrenia and ADHD are relatively evenly distributed statistically across geographical regions. In Scandinavia, there are around 400 potential hospitals and larger clinics in which investigations within the application area of SensoDetect® BERA are performed. Of these, a tenth are regarded by the board as significant centers for diagnosis. In Europe, there are around 8 000 hospitals and clinics which are potential customers for SensoDetect. Again, about a tenth constitute major centers.

Potential market: SensoDetect® BERA as a tool for research and development of pharmaceuticals

Two completed investigations show the SensoDetect® BERA's usefulness as an instrument for determination of the physiological effects of psychopharmaceutical drugs. Globally, the pharmaceutical market for schizophrenia and ADHD is worth more than 20 billion US dollars. In the related field of pharmacological development, objective methods such as SensoDetect® BERA are needed. In addition, future research in the field of neuroscience can be expected to benefit of SensoDetect® BERA.